In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
In a surprising announcement, Trump declares he will sign an executive order to slash prescription drug prices in the U.S. to match those of other high-income countries, potentially reducing costs by 30% to 80%.
